Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation.

In rats given intravenous L-NAME, central melanocortin 3/4 receptor activation by MTII caused a greater rise in mean arterial pressure than L-NAME plus vehicle or MTII alone.

In plain wordsIn rats, brain MTII raised blood pressure more when nitric oxide synthase was blocked in the body than with MTII alone.

Measurements

MAP increase

35 mm Hg

MTII with intravenous L-NAME

Source sentences

In rats given intravenous L-NAME, central MTII caused a greater rise in heart rate than L-NAME plus vehicle or MTII alone.

In plain wordsIn rats, brain MTII raised heart rate more when nitric oxide synthase was blocked in the body than with MTII alone.

Measurements

Heart rate increase

56 bpm

MTII with intravenous L-NAME

Source sentences

In rats, central MTII infusion reduced food intake by 58% and 50% during the first 6 days.

In plain wordsIn rats, MTII infused into the brain reduced food intake during the first 6 days.

Measurements

Food intake reduction

58%

first 6 days of MTII infusion

Food intake reduction

50%

first 6 days of MTII infusion

Source sentences

In rats, ICV MTII given with the challenge drug L-NAME caused about a 10 mm Hg rise in mean arterial pressure, similar to ICV MTII alone.

In plain wordsIn rats, brain MTII given with L-NAME raised blood pressure about as much as MTII alone.

Measurements

MAP increase

≈ 10 mm Hg

ICV L-NAME plus MTII

Source sentences

In rats, ICV MTII given with the challenge drug L-NAME caused no change in heart rate, similar to ICV MTII alone.

In plain wordsIn rats, brain MTII given with L-NAME did not change heart rate, like MTII alone.

Source sentences